Drugs that contain Cyclosporine

1. List of Cequa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10441630 SUN PHARM Topical formulations and uses thereof
Aug, 2033

(10 years from now)

US8980839 SUN PHARM Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
Aug, 2033

(10 years from now)

US9937225 SUN PHARM Topical formulations and uses thereof
Aug, 2033

(10 years from now)

US10918694 SUN PHARM Topical cyclosporine-containing formulations and uses thereof
Feb, 2037

(14 years from now)

Market Authorisation Date: 14 August, 2018

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

2. List of Restasis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648048 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8633162 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US9248191 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8685930 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8629111 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8642556 ALLERGAN Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(1 year, 6 months from now)

US8292129 ALLERGAN Dispensing device
Feb, 2031

(8 years from now)

US8561859 ALLERGAN Dispensing device
Apr, 2032

(9 years from now)

US9676525 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
Feb, 2034

(11 years from now)

US9669974 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
May, 2034

(11 years from now)

Market Authorisation Date: 23 December, 2002

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

How can I launch a generic of RESTASIS before it's patent expiration?
More Information on Dosage

3. List of Verkazia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7973081 SANTEN Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(2 years from now)

US9956289 SANTEN Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(2 years from now)

US8524779 SANTEN Emulsion compositions containing quaternary ammonium compounds
Jan, 2026

(2 years from now)

US9220694 SANTEN Emulsion compositions containing cetalkonium chloride
Jan, 2026

(2 years from now)

US8298568 SANTEN Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
Nov, 2027

(4 years from now)

US9132071 SANTEN Compositions containing quaternary ammonium compounds
Jun, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 23, 2028
New Product (NP) Jun 23, 2023

Market Authorisation Date: 23 June, 2021

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic